A high-profile Vancouver Island pot producer is taking steps to become a major medicinal marijuana supplier to another high-profile drug store chain.
In a March 22 press release, Tilray Canada Ltd. announced it has entered into a letter of intent “to become a preferred medical cannabis supplier” to Parmasave.
Subject to changes to regulations in Canada, which will allow the distribution, Tilray will supply and distribute its medical cannabis through pharmacists at Pharmasave, the press release said.
“Tilray’s products are available in 10 countries around the world. Our products can be purchased by patients in pharmacies in each of those countries except Canada. [The] announcement puts us in a strong position to expand the availability of our products to additional patients in need throughout Canada,” said Brendan Kennedy, Tilray CEO. “It’s exciting that we have the potential to bring our medical cannabis products to patients via pharmacies in Canada with a partner like Pharmasave, a company that shares our commitment to patient safety and access.”
Earlier this week, Tilray announced an agreement with Sandoz Canada Inc. According to a press release, Tilray has signed a binding letter of intent to be the exclusive collaborator with Sandoz to “accelerate innovation and increase availability” of medical cannabis products.
Pending regulatory approvals, Tilray will become the exclusive partner of Sandoz to work together on non-smokable medical cannabis products.
Two months ago, Tilray Canada announced a deal that will see it provide its medicinal marijuana to Shoppers Drug Mart.